Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study

FDA approved the initiation of Stage 2 of SetPoint Medical's pivotal IDE study based on the trial meeting the pre-specified criteria for interim analysis

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune disease, announced U.S. Food and Drug Administration (FDA) approval for continuation of the company’s RESET-RA study. The study, which received an Investigational Device Exemption (IDE) from the FDA to evaluate SetPoint Medical’s proprietary therapeutic platform in patients with rheumatoid arthritis (RA), was initiated in January 2021.

The primary purpose of the RESET-RA study, a two-staged, multicenter, randomized, sham-controlled, double-blind pivotal study, is to evaluate the safety and efficacy of SetPoint’s therapeutic platform in patients with moderate-to-severe RA who are incomplete responders or are intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). The primary efficacy endpoint is the proportion of patients achieving an ACR20 response in the treatment group compared to sham group at 12 weeks.

The RESET-RA study is designed to enroll up to 250 patients at 40 sites across the US in two stages with a planned interim analysis after completion of Stage 1. The enrollment of 60 patients in Stage 1 was completed in March 2022 at 18 sites in the US. The FDA approved study continuation with no changes to the study protocol following their review of both safety and efficacy outcomes from Stage 1.

“This is another significant milestone for SetPoint Medical as we continue to develop this novel treatment option for RA patients,” said David Chernoff, MD, Chief Medical Officer of SetPoint Medical. “There is a significant unmet medical need for new treatment alternatives for RA patients whose disease activity is inadequately controlled with conventional biologic or synthetic DMARDs. We look forward to enrolling the remaining 190 patients in the second stage of the study.”

The RESET-RA study is the first of its kind study to evaluate vagus nerve stimulation for treatment of RA. The vagus nerve plays an essential role in maintaining inflammatory balance, and therefore, is a target for treating chronic conditions associated with an imbalanced immune response. With approval for Stage 2, the RESET-RA study is now actively recruiting.

To learn more about RESET-RA, visit www.RESET-RA.study or go to NCT04539964.

About SetPoint Medical

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit www.setpointmedical.com.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.